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Abstract
Statins are widely used to lower cholesterol levels by inhibiting cholesterol biosynthesis. Some
evidence has indicated that statins might have therapeutic and preventive benefits for Alzheimer’s
disease (AD). We and others also have shown the beneficial effect of statin treatment in reversing
learning and memory deficits in animal models of AD. However, data from clinical trials are
inconclusive. We previously documented that the adenovirus vector encoding 11 tandem repeats
of Aβ1-6 fused to the receptor-binding domain (Ia) of Pseudomonas exotoxin A, AdPEDI-
(Aβ1-6)11, is effective in inducing an immune response against amyloid-β protein (Aβ) and
reducing brain Aβ load in Alzheimer’s mouse models. In the present study, we examined whether
the administration of simvastatin can modulate immune and behavioral responses of C57BL/6
mice to vaccination. Simvastatin was given to the animals as a diet admixture for four weeks,
followed by nasal vaccination with AdPEDI-(Aβ1-6)11 once per week for four weeks. The
cholesterol-lowering action of simvastatin was monitored by measuring the cholesterol levels in
plasma. Simvastatin significantly increased the number of the mice responding to vaccination
compared with the mice receiving only AdPEDI-(Aβ1-6)11. Immunoglobulin isotyping revealed
that the vaccination predominantly induced Th2 immune responses. Simvastatin treatment
prevented Aβ-induced production of IFN-γ in splenocytes. The adenovirus vaccination altered
mouse behavior in T- and elevated plus-maze tests and simvastatin counteracted such behavioral
changes. Our results indicate that simvastatin clearly enhances the immune responses of C57BL/6
mice to the nasal vaccination with AdPEDI-(Aβ1-6)11. Simvastatin may be effective in preventing
behavioral changes associated with vaccination.
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1. Introduction
Alzheimer’s disease (AD) is a slowly progressive neurodegenerative disease and the most
common type of dementia in the elderly. The characteristic pathological hallmarks of AD
include the significant loss of neurons in the cerebral cortex and certain subcortical regions,
the presence of intracellular neurofibrillary tangles and the formation of amyloid plaques
outside neurons and in cerebral blood vessels. The etiology of AD is still not clear, but
increasing lines of evidence support the hypothesis that accumulation of amyloid β-protein
(Aβ), the major component in amyloid plaques, is the causative factor in the development of
AD (Hardy and Selkoe, 2002; Price and Sisodia, 1994; Selkoe, 1994). The genetic
abnormalities that account for the buildup of Aβ deposits have been identified in some
autosomal dominant cases of AD, such as mutations in genes encoding presenilin-1 (PS1),
presenelin-2 (PS2) and beta-amyloid precursor protein (APP) (Goate et al., 1991; Kowalska
et al., 2004; Rogaev et al., 1995; Sherrington et al., 1995). Overexpression of the mutant
forms of these genes in transgenic mice led to the high levels of Aβ accumulation in the
brain as well as AD-like pathologic and behavioral alterations (Citron et al., 1997; Holcomb
et al., 1998; Games et al., 1995; Hsiao et al., 1996).
To date, no satisfactory treatment is available for AD. A number of immunotherapeutic
studies have shown that immunization with synthetic Aβ peptide prevented or reduced Aβ
deposits (Schenk et al., 1999) and attenuated the memory and learning deficits in animal
models of AD (Morgan et al., 2000; Janus et al., 2000). The clinical trials of Aβ1-42
vaccination (AN-1792) were halted because a subset of vaccinated patients (6%) developed
brain inflammation presumably caused by T-cell mediated immune responses (Gilman et al.,
2005; Nicoll et al., 2003; Orgogozo et al., 2003; Schenk and Yednock, 2002; Weiner and
Selkoe, 2002). Other problems associated with Aβ immunotherapy are that only 20% of AD
patients developed anti-Aβ antibodies due to poor immunogenicity of Aβ and aging (Gilman
et al., 2005) and that one AD patient and aged AD mouse models developed cerebral
microhemorrhages (Ferrer et al., 2004; Pfeifer et al., 2002; Racke et al., 2005). The
subsequent reports of the vaccination clinical trials indicate that Aβ immunotherapy is
effective in clearing Aβ deposits and improving cognitive deficits in a subset of AD patients
(Gilman et al., 2005; Nicoll et al., 2003; Hock et al., 2003). Therefore, it is crucial to find a
safe, efficacious immunotherapy. The synthetic Aβ1-42 peptide used in clinical trials
contains both B- and T- cell epitopes, with Aβ1-15 identified as a B cell epitope (Cribbs et
al., 2003; McLaurin et al., 2002; Town et al., 2001) and Aβ6-28 as a T cell epitope (Cribbs
et al., 2003). To avoid the T-cell mediated side effects, we previously constructed an
adenovirus vector encoding 11 tandem repeats of Aβ1-6 fused to the receptor-binding
domain (Ia) of Pseudomonas exotoxin A, AdPEDI-(Aβ1-6)11 (Kim et al., 2005). The
immunization study revealed that AdPEDI-(Aβ1-6)11 predominantly induced IgG1 isotype
anti-Aβ antibodies (Kim et al., 2005) and upregulated IL-10 expression in AD mouse
models (Kim et al., 2007b). The above results indicate that vaccination with AdPEDI-
(Aβ1-6)11 effectively induces the Th2-type immune responses against Aβ.
Statins, the 3-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reductase inhibitors, are widely
used in clinical practice to lower cholesterol levels by inhibiting cholesterol biosynthesis. In
addition to the cholesterol lowering effect, statins have many pleiotropic effects such as
reducing Aβ production, suppressing inflammatory responses, stabilizing the blood-brain
barrier integrity, protecting neurons from excitotoxins, apoptosis and oxidative stresses, and
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promoting synaptogenesis (Liao and Laufs, 2005; McFarlane et al., 2002; Wang et al.,
2008). While several retrospective studies reported beneficial effects of statins on preventing
AD (Jick et al., 2000; Li et al., 2007; Wolozin et al., 2000; Zamrini et al., 2004), others did
not, or even on the cognitive function of the elderly (Li et al., 2004; Shepherd et al., 2002).
Potentially beneficial effects of statins on AD have been demonstrated by a number of
investigators using cell culture and animal models. For example, simvastatin and lovastatin
were shown to reduce Aβ42 and Aβ40 levels in primary cultures of hippocampal and
neocortical neurons and in the cerebrospinal fluid and brain homogenates in guinea pigs
(Fassbender et al., 2001). Atorvastatin remarkably attenuated Aβ deposition in the brain of
an AD mouse model (Petanceska et al., 2002). We also have shown that simvastatin was
effective in reversing learning and memory deficits of an aged AD mouse model (Li et al.,
2006). These results suggest that statins may have a beneficial role in preventing and/or
treating AD. The other effects of statins, such as suppressing inflammation and stabilizing
the blood-brain barrier integrity, may be beneficial to AD immunotherapy, particularly in
avoiding its side effects, as well as sickness behaviors that may be evoked through the
circulation by increases in proinflammatory cytokines associated with vaccinations. In the
current study, we tested the feasibility of the combined treatment of an adenovirus vaccine,
AdPEDI-(Aβ1-6)11, with simvastatin in young C57BL/6 mice by determining the effects of
vaccination and/or statin treatment on their immune responses and behavioral functions such
as exploratory activity, anxiety, and motor coordination.
2. Results
2.1. Simvastatin treatment
Two groups of 10 mice were treated daily with 50 mg/kg of simvastatin for 13 weeks. The
total cholesterol levels in plasma were measured at 4 weeks (week 4) after the initiation of
simvastatin treatment. Simvastatin treatment significantly reduced the total plasma
cholesterol levels by 15% compared to the mice consuming regular diet without simvastatin
(Table 1). There was no difference in the total cholesterol levels between simvastatin only
and simvastatin plus AdPEDI-(Aβ1-6)11 groups. No difference in the total cholesterol levels
was found between PBS only and AdPEDI-(Aβ1-6)11 only groups, also. During the
treatment period, there were no differences in physical appearance, body weight, food
consumption, or mortality among the groups (data not shown). Long-term treatment with 50
mg/kg of simvastatin did not cause any generalized toxicity.
2.2. Anti-Aβ antibody titers and IgG isotyping
Two groups of 10 mice were subjected to nasal AdPEDI-(Aβ1-6)11 inoculations 5 times at
weeks 4, 5, 6, 7 and 10 with and without simvastatin treatment (Fig. 1; Table 1). Anti-Aβ
antibody titers were determined by enzyme-linked immunosorbent assay (ELISA) using sera
at weeks 0, 4, 7, 10 and 13. The data on immune responses, anti-Aβ antibody titers and
isotyping are summarized in Table 2. At week 7, 9 out of 10 mice treated with simvastatin
together with AdPEDI-(Aβ1-6)11 developed anti-Aβ titers (seropositive) while AdPEDI-
(Aβ1-6)11 vaccination without simvastatin elicited anti-Aβ titers in 5 out of 10 mice. When
only the seropositive mice were compared at week 7, the mean serum titer (1.9 ± 0.7 µg/ml)
of mice subjected to the combination treatment of AdPEDI-(Aβ1-6)11 and simvastatin was
similar to that (1.8 ± 1.2 µg/ml) of mice treated with only AdPEDI-(Aβ1-6)11. At weeks 10
and 13, the seropositive rates and the average anti-Aβ titers of seropositive mice receiving
AdPEDI-(Aβ1-6)11 only stayed at almost the same levels. Although the number of
seropositive mice subjected to the combination treatment gradually decreased from 9 to 7
and 6 at weeks 10 and 13, respectively, the mean anti-Aβ titer (8.8 ± 2.4 µg/ml) of
seropositive mice receiving the combination treatment at week 13 increased approximately
4-fold from weeks 7 and 10 (P < 0.05) and was significantly higher than that (2.5 ± 0.8 µg/
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ml) of seropositive mice treated with AdPEDI-(Aβ1-6)11 alone (P = 0.03). Thus, simvastatin
treatment appears to increase seropositive rates in its early stages as well as antibody titers in
its later stages in susceptible animals. As expected, anti-Aβ IgG in mice receiving phosphate
buffered saline (PBS) or simvastatin only were undetectable by ELISA.
Immunoglobulin isotype-specific anti-Aβ titers were quantified by ELISA. The IgG
isotyping revealed that the anti-Aβ antibodies induced by nasal vaccination with AdPEDI-
(Aβ1-6)11 were predominantly of the IgG1 isotype in both groups regardless of the
simvastatin treatment (Table 2). The measurement of anti-Aβ IgG2a in both groups is below
the detectable level by ELISA.
2.3. ELISPOT assay for IFN-γ
In addition to IgG antibody isotyping, to examine whether simvastatin can prevent Th1-type
immune responses, enzyme-linked immunospot (ELISPOT) assay was carried out for
determining the numbers of IFN-γ-producing cells in splenocytes from each mouse after the
last AdPEDI-(Aβ1-6)11 immunization (week 13). The results are shown in Figure 2; in both
PBS only and AdPEDI-(Aβ1-6)11 only treatment groups, the stimulation with Aβ1-42
peptide significantly increased the numbers of IFN-γ-producing splenocytes more than 4-
fold compared to the non-stimulus conditions (P < 0.05). However, in the groups consuming
simvastatin food, regardless of AdPEDI-(Aβ1-6)11 vaccination, the presence of Aβ1-42
peptide did not increase the number of IFN-γ-producing splenocytes. Thus, simvastatin
treatment successfully prevented Aβ-induced production of IFN-γ in splenocytes.
2.4. Exploratory activity, anxiety and motor coordination
To investigate possible effects of treatment on behavioral functions, mice were subjected to
tests starting at week 8 after the completion of 4 vaccinations (Fig. 1). The exploratory
tendencies were examined in T-maze spontaneous alternation, open-field, and elevated plus-
maze tests, while motor coordination was measured in stationary beam, coat-hanger, and
rotorod tests.
In T-maze spontaneous alternation test, the tendency of mice to switch arm choices on
successive trials was evaluated. Thus, T-maze is a test dependent on working memory,
anxiety levels, and cerebral activation. The mean spontaneous alternation rate was above the
50% chance level in all groups (P < 0.05, Mann-Whitney U test) (Table 3). There was a
significant interaction in alternation rate between vaccine and simvastatin (F(1,35)=6.19, P <
0.05), due to the higher rate of mice treated with AdPEDI-(Aβ1-6)11 alone. Thus,
simvastatin counteracted the effect of adenovirus vaccination. There was no difference in
choice trial latencies.
In the elevated plus-maze test (Table 3), mice chose to explore either safe (enclosed) or
anxiogenic (open) arms. On the initial testing day, there was a significant interaction in open
arm entries (F(1,35)=10.64, P < 0.01), lower in the group receiving either AdPEDI-
(Aβ1-6)11 or simvastatin alone relative to the others. Thus, combination treatment cancelled
the anxiogenic effects of each treatment. No intergroup difference was evident for open arm
duration, enclosed arm entries and duration, or for any measure on the following day (P >
0.05).
In the coat-hanger test (Table 4), mice treated with simvastatin regardless of adenovirus
vaccination took a longer time before reaching the extremity of the horizontal wire (MT-2,
F(1,35)=4.33, P < 0.05), with no difference found for any other measure.
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In the rotorod test (Table 4), mice treated with simvastatin regardless of adenovirus
vaccination stayed on the beam longer on the third trial block (F(1,35)=4.59, P < 0.05),
indicating an improvement in motor coordination.
There was no intergroup difference for any measure in open-field and stationary beam tests
(P > 0.05, data not shown).
It is possible that seronegative mice after nasal vaccination with AdPEDI-(Aβ1-6)11 may
behave differently from seropositive mice. Therefore, we omitted seronegative mice from
the two groups subjected to AdPEDI-(Aβ1-6)11 vaccination and, then, performed statistical
analyses for intergroup differences in all the behavioral tests. The same intergroup
differences were found in elevated plus-maze, coat-hanger, and rotorod tests even after
deleting seronegative mice (P < 0.05, data not shown). No intergroup difference, however,
was found for any measure in T maze. Thus, the improved alteration rate in the entire set of
the AdPEDI-(Aβ1-6)11 only group in T maze is not due to the seropositivity (P > 0.05, data
not shown). There was no intergroup difference for any measure in open-field and stationary
beam tests, also (P > 0.05, data not shown).
3. Discussion
Immunomodulatory effects of statins on vaccination have been shown previously. In
agreement with our observations, Lee et al. (2006) reported that a 10-day treatment with
atorvastatin (40 mg) increased by a factor of 3 the humoral response of normal healthy
volunteers receiving a tetanus toxoid followed by a booster on the fifth day. They suggested
the use of statins to enhance humoral response to vaccination. On the contrary, Packard et al.
(2007) found no differences in serum titers between an atorvastatin and placebo group of
young healthy subjects after hepatitis A vaccination. In the latter study, atorvastatin
treatment (40 mg) began on the same day as vaccination. The hepatitis A vaccine is
considered to be a stronger antigen than tetanus toxoid, with a seroconversion rate higher
than 98%. Therefore, the seroconversion rates cannot be compared between the two groups.
Packard et al. (2007) also stated that atorvastatin treatment did not influence antibody
responses in BALB/c mice subjected to vaccination of either a combined diphtheria-tetanus-
pertussis-polio-Hib-hepatitis B vaccine or diphtheria-hepatitis vaccine. We, however, found
that simvastatin treatment increased the seroconversion rate on average at the early
treatment stage and the antibody titers at the later stage in C57BL/6 mice immunized with
AdPEDI-(Aβ1-6)11. As we reported previously (Kim et al., 2005), when BALB/c and
C57BL/6 mice were immunized with the same adenovirus vaccine only, the seroconversion
rates were 100% and 57%, respectively. Therefore, statins may be more effective in
enhancing immunoresponses to weak antigens and/or in immunocompromised subjects like
the elderly.
While 50–60% of mice receiving only AdPEDI-(Aβ1-6)11 developed sizable anti-Aβ
antibodies [this study and our previous study (Kim et al., 2005)], simvastatin treatment
increased the number of the seropositive mice to 90% after 4 vaccinations (week 7). This
finding is highly significant because only 20% of AD patients developed anti-Aβ antibodies
in a phase II clinical trial of AN-1792 vaccine presumably due to low immunogenicity of Aβ
and/or reduced immune responses in the elderly (Monsonego et al., 2001; Monsonego,
2005). The seroconversion rate of the combination treatment group dropped to 60% after the
fifth vaccination (week 13) although the mean serum titer of the seropositive mice in the
same group significantly increased. The reasons for the decrease in the seropositive rate at
the late treatment stage are not clear. Because lovastatin treatment increases regulatory T
(Treg) cells at the inflammation site in C57BL/6 mice (Mira et al., 2008), such an increase in
Treg cells may induce immunological tolerance to antigens in susceptible animals
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(Hasselberg et al., 2009; Sun et al., 2010). In this regard, fine-tuning of the statin dosage as
well as its duration is required to optimize beneficial effects of statins for AD
immunotherapy: maximizing Th2 responses and minimizing adverse effects as well as
immunological tolerance.
Due to meningoencephalitis presumably induced by Th1 responses associated with Aβ
vaccination (Check, 2002; Nicoll et al., 2003; Orgogozo et al., 2003), the development of
successful therapeutic vaccines against AD is thought to depend on identification of
immunization strategies that can induce potent Aβ-specific anti-inflammatory Th2 responses
while minimizing Th1 responses. We previously documented that nasal immunization with
AdPEDI-(Aβ1-6)11 strongly polarized anti-inflammatory Th2 type response in mice (Kim et
al., 2005; Kim et al., 2007a; Kim et al., 2007b). In the current study, regardless of the
simvastatin treatment, IgG1 predominated in anti-Aβ antibodies induced by nasal
vaccination of AdPEDI-(Aβ1-6)11 and anti-Aβ IgG2a was undetectable. In mice, the
production of IgG1 is primarily induced by Th2-type cytokines, while IgG2a is produced
through Th1-type cytokines. Thus, our observations are consistent with regard to nasal
vaccination of AdPEDI-(Aβ1-6)11. Statins appear to have dual effects on two qualitatively
different types of adaptive immune responses: enhancing anti-inflammatory Th2 and
inhibiting pro-inflammatory Th1 responses. The mechanism by which statins promote a shift
from a Th1-type response toward a Th2-type response was described in the previous studies
(Arora et al., 2006; Ho and Glimcher, 2002; Murphy and Reiner, 2002; Robinson and
O'Garra, 2002). Statin-treated dendritic cells promote Th2-cell differentiation by inducing
expression of GATA-binding protein 3 (GATA3) and inhibit Th1 differentiation by
downregulating activation of nuclear factor-κB (NF-κB) and T-bet (a T-box transcription
factor) in CD4+ T cells. Furthermore, we have shown that simvastatin suppressed Aβ-
induced proliferation of IFN-γ-producing splenocytes. This finding is consistent with the
previous reports showing that statins suppress expression of Th1 type cytokines including
IFN-γ (Arora et al., 2006; Hakamada-Taguchi et al., 2003). Naïve CD4 T-cells activated in
the presence of IL-2 and IFN-γ tend to develop into Th1-cells and IFN-γ inhibits the
proliferation of Th2-cells. The inhibition of IFN-γ production and Th1 differentiation by
statins might have a significant role in providing a neuro-protective effect during Aβ
vaccination because Aβ-induced meningoencephalitis is IFN-γ dependent and is associated
with infiltration of Aβ-specific T cells in an animal model of AD (Monsonego et al., 2006).
In response to Aβ stimulation, splenocites from mice in both PBS only and AdPEDI-
(Aβ1-6)11 only treatment groups produced IFN-γ (Fig. 2). Because stimulation with Aβ is
reported to increase production of IFN-γ in endothelial cells (Suo et al., 1998) and co-
cultures of microglia and astrocytes (Yamamoto et al., 2007), this induction of IFN-γ in the
PBS group does not represent antigen-specific T-cell responses. Nevertheless, our results
indicate that statins are effective in inhibition of IFN-γ production by Aβ stimulation
regardless of vaccination.
A broad spectrum of adverse effects of vaccines has been reported (Siegrist, 2007).
Enhancing immunogenicity of vaccines can increase such adverse reactions (Jacobson et al.,
2001). It is essential for successful vaccination to evoke innate immune responses prior to
activation of adaptive immune responses. Activated innate and adaptive cells, however,
produce pro-inflammatory cytokines acting on the brain through the circulation, altering
brain functions and resulting in sickness, including affective, cognitive, and physical
symptoms such as anxiety, depression, decreased motivation, impaired memory, and
decreases in physical activities (Dantzer et al., 2008). Indeed, Salmonella typhi vaccine was
used to model sickness behavior (Brydon et al., 2009; Wright et al., 2005). Therefore, we
investigated possible adverse effects of our vaccination modalities on several behavioral
tests. The only adverse effect of adenovirus vaccination was an increase in anxiety in the
elevated plus-maze, an effect counteracted by simvastatin. In contrast, adenovirus
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vaccination had no effect on motor coordination and even improved the alternation rate of
mice in the T-maze, and this effect was also counteracted by simvastatin. Thus, simvastatin
counteracted both adverse and positive actions of vaccine treatment. Simvastatin alone
improved motor coordination on the rotorod while slowing down motor speed on the
horizontal bar of the coat-hanger. Overall, simvastatin appears to maximize the ability to
coordinate movements on a moving beam, though at the expense of retarding movements on
a stationary bar. The latter results are consistent with our previous observation that
simvastatin treatment normalized hyperactivity of Tg2576 mice, an animal model of AD, in
the open field test (Li et al., 2006). Thus, statins may have a calming effect on animals,
which needs to be validated in the future.
The molecular mechanisms by which simvastatin offsets these alterations induced by
adenovirus vaccination should be further explored. Because statins can reduce expression,
production and circulating levels of proinflammatory cytokines such as tumor necrosis
factor-α, IL-6 and IL-1β (Rosenson, 2001; Morgan et al., 2009; Youssef et al., 2002;
Aprahamian et al., 2006; Aktas et al., 2003; Shimada et al., 2006), statins may ameliorate
the negative impact of vaccines.
4. Methods and Materials
4.1. Preparation of AdPEDI-Aβ(1-6)11
AdPEDI-Aβ(1-6)11, was prepared as previously described (Kim et al., 2005).
4.2. Animals and treatments
C57BL/6 mice (6–8 weeks old, female) were obtained from Jackson Laboratories. Mice
were randomly assigned to 4 treatment groups in such a manner as there was no significant
intergroup difference in body weight. The 4 groups (n=10) were subjected to treatment with
PBS, simvastatin, AdPEDI-(Aβ1-6)11 or simvastatin plus AdPEDI-(Aβ1-6)11. The
simvastatin treatment groups were fed with a diet admixture containing 0.03% of
simvastatin so that each mouse consumed a daily dose of approximately 50 mg simvastatin/
kg body weight. Four weeks after the initiation of the simvastatin treatment, mice were
nasally vaccinated with AdPEDI-Aβ(1-6)11 once every week for 4 weeks followed by a final
booster shot on week 10 (Fig 1). Nasal vaccination was carried out by pipetting 1 × 108
plaque forming unites (PFU) of AdPEDI-(Aβ1-6)11 in 20 µl PBS into one of the nostrils of
an anesthetized mouse. Control mice received the same amount of PBS. After the fourth
vaccination, mice were subjected to behavioral assessment. Three weeks after the final
vaccination, mice were sacrificed and their spleens were collected for isolation of
splenocytes. A blood sample was taken through the tail vein at 0, 4, 7, 10 and 13 weeks after
the initial vaccination to determine the levels of total cholesterol, anti-Aβ antibodies and the
immunoglobulin isotypes. All animal protocols used for this study were prospectively
reviewed and approved by the Institutional Animal Care and Use Committees of the
University of Illinois College of Medicine at Peoria and the University of Alabama at
Birmingham (UAB).
4.3. Determination of total cholesterol level in plasma
Plasma was prepared by centrifuging blood samples at 1500 × g for 10 min at room
temperature. The total cholesterol levels in plasma were determined colorimetrically with
commercial reagents (Infinity™ cholesterol reagent; Thermo Electron Corporation,
Melbourne, Australia).
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4.4. Determination of anti-Aβ antibodies in sera
The blood samples were incubated at room temperature for 1 h then transferred to 4°C. After
overnight incubation, sera were separated by centrifugation at 10,000 × g for 10 min. Sera
were stored at −80°C and thawed at the time of assay. ELISA was carried out to determine
the titer of anti-Aβ antibodies and the immunoglobulin isotypes as previously described
(Kim et al., 2005). To be brief, 96-well plate was coated with 500 ng synthetic Aβ1-42
peptide per well at 4°C overnight, followed by incubation with blocking buffer (1x PBS
containing 0.5% BSA, 0.05% Tween-20 and 5% goat serum) at room temperature for 1 h.
Then, diluted serum samples were added to microtiter wells and incubated at 4°C overnight.
The next day, microtiter wells were washed 5 times using washing buffer (1x PBS
containing 0.05% Tween-20), and then incubated with an appropriate horseradish
peroxidase (HRP)-conjugated secondary antibody at room temperature for 1 h. In the
following step, microtiter wells were washed with the washing buffer 5 times and then
incubated with 100 µl of 3,3’,5,5’-tetramethylbenzidine (TMB) for 15 min. The reaction was
stopped by adding 100 µl of 1 N H2SO4. The optic densities were determined at 450 nm
using Microplate Reader. Serial dilutions of 6E10 (monoclonal anti-Aβ antibody) were used
as the standard to determine the titer of anti-Aβ antibodies in the sera. Therefore, the
concentrations (µg/ml) of the serum titers presented here reflect the concentrations of 6E10
antibody, which produce the same ELISA readings, and may not accurately represent the
absolute amounts. Comparison of treatment groups was performed by one-way analysis of
variance (ANOVA) and two-tailed Student’s t-test. P < 0.05 was considered statistically
significant.
4.5. Detection of IFN-γ-producing cells by ELISPOT
Spleens were individually isolated from mice. Single cell suspension of splenocytes was
prepared by homogenizing a spleen tissue in 10 ml of RPMI 1640 medium and forcing cells
through a cell strainer with 70 µm pores. Splenocytes were centrifuged at 380 g for 6 min
and resuspended with 0.8 ml ACK lysing buffer (UAB Comprehensive Cancer Center) to
lyse red blood cells. Cell suspension was centrifuged again at 380 g for 6 min and final cell
pellets were suspended in RPMI 1640 medium supplemented with 10% fetal bovine serum,
100 U/ml penicillin, 100 µg/ml streptomycin and 20 µM 2-mercaptoethanol. The number of
IFN-γ-producing splenocytes was determined by ELISPOT assay kit (eBioscience). To be
brief, a 96-well PVDF membrane ELISPOT plate (Millipore) was coated with anti-mouse
IFN-γ capture antibody at 4°C overnight and then treated with the blocking buffer for 2 h at
room temperature. After washing with the washing buffer 3 times, 5 × 105 splenocytes were
seeded in each well and stimulated by adding 100 µl of the culture medium containing
Aβ1-42 at 10 µg/ml. After incubation at 37°C for 24 h, the medium was aspirated and the
plate was washed with washing buffer (1x PBS containing 0.05% Tween-20). The detection
antibody was then added to the 96-well plate and incubated at room temperature. Two hours
later, the plate was washed 3 times and incubated with Streptavidin-HRP for 1 h. The 3-
Amino-9-Ethylcarbazole (AEC) substrate solution (Sigma) was added to each well, and
allowed to stand for development of the spots. The plate was air-dried in a hood and the
spots were scanned by Immunospot Plate Scanning Services (CTL analyzers LLC,
Cleveland OH).
4.6. Assessment of behavioral functions
The behavioral alterations potentially associated with vaccination and statin treatment were
tested in the methods previously described (Lalonde et al., 2005). For each test day,
spontaneous alternation was evaluated first, followed by open-field (days 1 to 3), elevated
plus-maze (days 4 and 5), stationary beam (day 6), coat-hanger (day 6), and rotorod (days 7
to 9) tests.
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Spontaneous alternation was tested with a T-maze. The maze was made of white acrylic and
consisted of a central stem flanked on each side by 2 arms. The maze width was 9 cm, the
wall height was 20 cm, and each arm was 30 cm in length. On the initial trial, the mice were
placed in the stem with the right arm blocked by a plastic barrier (forced choice). After
entering the available arm, the mice were kept in it for 1 min by closing the barrier behind
them. The mice were then retrieved and after removing the barrier placed back in the stem
for a free-choice trial, either into the same arm or the opposite one (4-paw criterion). On the
following 9 days, the same 2-trial procedure was repeated, except that the blocked arm was
switched from right on odd days to left on even days. The number of alternations and
latencies before responding during the choice trial was measured.
Motor activity was measured in the open-field made of white acrylic with a 50 cm × 50 cm
surface area. A mouse was placed in a corner of the open field. The activity in central zone
(25 cm × 25 cm surface) and peripheral zone was recorded in a 5-min session for 3
consecutive days and analyzed by video tracking software (SD Instruments, San Diego,
CA). The distance travelled and the time spent resting (<2 cm/s), moving slow (2- cm/s),
moving fast (>5 cm/s) in each zone were measured, as well as the time spent in the
periphery and center of the apparatus.
The elevated plus-maze consisted of 4 arms in a cross-shaped form with a 10 cm × 10 cm
central region. Two of the arms were enclosed on 3 sides by walls (10 cm in height) which
faced each other while the other 2 were open, except for a minimal border (0.5 cm in height)
used to minimize falls. A mouse was placed in the central region and then the number of
entries and the time spent in enclosed and open arms were measured in a 5-min session for 2
continuous days. The open/total arm entries and duration ratios were calculated.
The stationary beam (diameter: 2.5 cm; length: 110 cm) was made of plastic covered by
white masking tape to facilitate a firm grip. The beam was divided into 11 segments along
its length and placed at a 40 cm height from a cushioned floor to prevent injury. A cardboard
wall was inserted at each end to prevent escape. A trial began by placing the mice on the
middle segment. The number of segments crossed (4-paw criterion), the latencies before
falling, and the number of falls were measured in a single 4-trial session, with a 1 min cut-
off period and a 15 min intertrial interval.
Motor speed was measured in the coat-hanger test. The triangular-shaped coat-hanger
consisted of a horizontal steel wire (diameter: 2 mm, length: 41 cm) flanked at each end by 2
side-bars (length: 19 cm; inclination: 35° from the horizontal axis). The horizontal bar was
placed at a 40 cm height from a cushioned floor. The mice were placed upside-down in the
middle of the horizontal wire and released only after gripping with all 4 paws. Seven types
of movement time (MT) were compiled, namely latencies before reaching (snout criterion)
the first 10 cm segment (MT-1) or the extremity (MT-2) of the horizontal wire, latencies
before reaching either side-bar with 2, 3 or 4 paws, and latencies before reaching (snout
criterion) either the midway or the top of the side-bar. The latencies before falling and the
number of falls were also measured. A trial ended when the mice either fell or reached the
top of the apparatus. In the latter case, a maximal score of 60 s was given for latencies. This
test was performed in a single session of 4 trials. For each trial, there was a 1 min cut-off
period and a 15 min intertrial interval.
The accelerating rotorod (Model 7650, Stoelting, Wood Dale, IL, USA) consisted of a beam
(diameter: 3 cm) made of ribbed plastic, elevated at a 13.5 cm height, and separated into 5
sections (width: 5.5 cm) by a plastic barrier. Facing away from the experimenter's view, the
mice were placed on top of the already revolving rod (4 rpm) in the orientation opposite to
its movement, so that falls could be avoided by forward locomotion. The rotorod accelerated
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gradually and smoothly from 4 to 40 rpm during the 5-min trial. Latencies before falling
were measured in 4-trial sessions for 3 days, with a 15 min intertrial interval. Whenever a
mouse clung to the rod without moving (passive rotation) for 2 complete revolutions in
succession, it was retrieved and a fall registered.
4.7. Statistical Analysis
Student’s t test was used to determine the significant difference in the total plasma
cholesterol level and the anti-Aβ antibody titers between the treatment groups. The
measurement of IFNγ was analyzed by one-way ANOVA followed by Turkey’s post hoc
test. The rotorod test was analyzed by a two-way ANOVA with repeated measurements on
the trial factor. For the other tests, intergroup differences were evaluated by unpaired t-tests.
In the spontaneous alternation test, groups were each compared with the Mann-Whitney U
test to a theoretical group performing at 50% chance. In all cases, P < 0.05 was considered
to be statistically significant.
5. Conclusion
The phase II clinical trial of AN-1792 vaccine revealed serious problems associated with
this modality: (1) meningoencephalitis presumably caused by T-cell mediated autoimmune
responses (Check, 2002; Nicoll et al., 2003; Orgogozo et al., 2003), (2) low immunogenicity
of Aβ and reduced immune responses in the elderly (Monsonego et al., 2001; Monsonego,
2005) and (3) cerebral hemorrhages (Ferrer et al., 2004; Pfeifer et al., 2002; Racke et al.,
2005; Wilcock et al., 2003). Therefore, safe and effective modalities for AD immunotherapy
are yet to be identified. We propose to use statins to circumvent the problems. To test the
feasibility in this study, C57BL/6 mice were subjected to combined treatment of AdPEDI-
(Aβ1-6)11 vaccine and simvastatin and the results were compared to those from single-agent
treatment. Simvastatin treatment appeared to increase the seropositive rate of vaccinated
mice in its early stage and boosted the antibody titers by 350% in the late stage. Simvastatin
treatment inhibited Aβ-induced proliferation of IFN-γ-producing splenocytes. Furthermore,
simvastatin treatment counteracted some behavioral alterations that were associated with
AdPEDI-(Aβ1-6)11 vaccination. These results suggest that combined treatment of Aβ-
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Simvastatin treatment and immunization schedule.
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ELISPOT assay to detect the immune responses against Aβ in splenocytes. Splenocytes
were isolated from experimental animals and cultured in the presence or absence of 10 µg/
ml of Aβ1-42 for 24 h. IFN-γ-producing splenocytes were determined by ELISPOT assay.
For splenocytes isolated from the PBS- and AdPEDI-(Aβ1-6)11-treated mice, the numbers of
IFN-γ-producing cells increased in response to Aβ stimulation (*P < 0.05). For mice treated
with simvastatin regardless of AdPEDI-(Aβ1-6)11 vaccination, Aβ stimulation did not
increase IFN-γ-producing splenocytes.
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Table 1
Treatment Groups
Plasma PBS Adv simvastatin simvastatin + Adv
Total Cholesterol (mg/dl) 112.25±3.4 114.1±3.2 93.4±3.3a 100.0±4.1a
Plasma cholesterol levels after simvastatin administration. (N=10 for each treatment group,
a
P < 0.05).




















Ig isotypes of Aβ42
antibodies
Week 7
  AdPEDI-(Aβ1-6)11 only 5/10 1.8±1.2 IgG1 >> IgG2aa
  AdPEDI-(Aβ1-6)11 + simvastatin 9/10 1.9±0.7 IgG1 >> IgG2aa
Week 10
  AdPEDI-(Aβ1-6)11 only 5/10 1.9±1.0 IgG1 >> IgG2aa
  AdPEDI-(Aβ1-6)11 + simvastatin 7/10 2.3±0.9 IgG1 >> IgG2aa
Week 13
  AdPEDI-(Aβ1-6)11 only 6/10 2.5±0.8 IgG1 >> IgG2aa
  AdPEDI-(Aβ1-6)11 + simvastatin 6/10 8.8±2.4b IgG1 >> IgG2aa
Characterization of anti-Aβ antibodies induced by AdPEDI-(Aβ1-6)11 vaccination with or without simvastatin.
a
Levels of anti-Aβ IgG2a were less than the minimum detectable level by the isotype-specific ELISA.
b
P = 0.03.
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Table 3
Test PBS simvastatin Adv simvastatin +
Adv
T-maze
  Alternations (%) 63±4 69±4 77±3a 64±3
  Choice latencies/trial (s)  8±1 10±1 10±1  8±1
Elevated plus-maze
  Open arm entries 13±1 10±1b 10±0.7b 14±1
  Enclosed arm entries 16±1 16±2 14±1 15±1
  Open/total entries (%) 46±2 37±4a 433 47±3
  Open arm duration (s) 67±8 60±10 69±7 79±6
  Enclosed arm duration (s) 163±9 181±10 163±7 148±5
  Open/total duration (%) 22±3 20±3 23±2 26±2
Effects of vaccine and simvastatin on exploratory activity in C57BL/6J mice. Values are means ± S.E.M.,
a
P < 0.05, and
b
P < 0.01 vs other groups.
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Table 4
Tests PBS simvastatin Adv simvastatin +
Adv
Coat-hanger
MT-1 (s) 51±12 64±18 28±9 64±18
MT-2 (s) 102±17 124±22a 67±12 120±20a
2-paw (s) 151±17 163±21 122±14 169±16
3-paw (s) 183±14 202±12a 187±14 220±7a
4-paw (s) 230±5 214±8a 197±14 230±5a
Midway (s) 205±12 227±4 220±9 231±5
Top (s) 214±9 231±3 232±5 233±5
Fall latencies 214±9 232±3 232±5 233±5
Rotorod
Trial 1 (s) 118±31 162±31 60±27 116±38
Trials 2 (s) 181±30 184±37 143±35 176±40
Trial 3 (s) 227±29 250±28a 172±32 270±22a
Trial 4 (s) 229±32 261±27 196±31 264±21
Effects of vaccine and simvastatin on motor coordination in C57BL/6J mice. Values are means ± S.E.M., and
a
P < 0.05 vs other groups.
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